Target intelligence / Profile preview

Human serum albumin (HSA) Cysteine-34 (HSA (Cys34))

Target
HSA (Cys34)
Molecular classification
Plasma protein, Carrier protein, Antioxidant
01

Overview

Human serum albumin (HSA) is the most abundant protein in human plasma, and its Cysteine-34 (Cys34) residue is the only free thiol group among its 35 cysteine residues (UniProt P02768). This specific residue serves as the primary extracellular antioxidant, accounting for approximately 80% of the thiol-based radical scavenging capacity in the blood (PubMed: 18482394). Under physiological conditions, Cys34 exists mostly in a reduced state known as human mercaptalbumin (HMA), but it is susceptible to oxidation to human non-mercaptalbumin (HNA) during systemic inflammation or oxidative stress (PubMed: 25503335). Beyond its redox role, Cys34 is a key site for the covalent attachment of drugs, particularly those designed for long-circulating prodrug delivery systems like Aldoxorubicin (PubMed: 24138310). It also interacts with metal-based therapeutics such as cisplatin and gold-based drugs, significantly influencing the pharmacokinetics and toxicity profiles of various pharmacological agents (PubMed: 22403074).

Other names
AlbuminSerum albuminCys34MercaptalbuminHuman mercaptalbuminHuman non-mercaptalbuminHMAHNA
02

Mechanism of action

Covalent conjugation to the free thiol group, thiol-disulfide exchange, and scavenging of reactive oxygen and nitrogen species.

03

Biological functions

Antioxidant activityRedox regulationLigand transportMaintenance of oncotic pressurepH buffering
04

Disease associations

Oxidative stressLiver cirrhosisChronic kidney diseaseSepsisInflammationDiabetes mellitus
05

Safety considerations

HypoalbuminemiaDrug-drug interactions due to binding competitionAltered pharmacokinetics in liver or kidney disease
06

Interacting drugs

Aldoxorubicin

4 more in the full profile.

07

Biomarkers

Human mercaptalbumin (HMA) levelHuman non-mercaptalbumin (HNA) levelAlbumin redox state

Beyond the preview

Go deeper on Human serum albumin (HSA) Cysteine-34 (HSA (Cys34)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Human serum albumin (HSA) Cysteine-34 (HSA (Cys34)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call